title: Intralesional PV-10 for in-transit melanoma-A single-center experience.
abstract: OBJECTIVE
  Patients with in-transit melanoma metastasis have longer median survival than patients with distant metastatic disease. Furthermore, local disease control is an important endpoint for symptom management. The treatment of unresectable loco-regional recurrence or in-transit disease has been historically managed with a combination of treatments including surgery, radiotherapy, isolated limb infusion or perfusion as well as systemic therapies. Intralesional PV-10 has been used at Peter MacCallum Cancer Centre since 2010, and the current report presents a retrospective analysis of patient outcomes, reporting the response rates, durability of responses, and observed toxicities.
  
  
  METHODS
  Records were analyzed retrieving details of 19 patients treated with PV-10 over a 4-year period from 2010 to 2014. Medical records were reviewed for these patients and data extracted.
  
  
  RESULTS
  Nineteen patients with in-transit melanoma were treated with intralesional PV-10 between 2010 and 2014. Disease control (complete or partial response or disease stability) was achieved in 68% of patients with 26% having a complete response. This was achieved with minimal associated toxicity.
  
  
  CONCLUSIONS
  PV-10 is an effective, durable, well-tolerated treatment tool with an acceptable side effect profile for the management of unresectable in-transit melanoma. J. Surg. Oncol. 2016;114:380-384. © 2016 Wiley Periodicals, Inc.
authors.affiliation: Division of Cancer Surgery, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
authors.forename: Jocelyn
authors.initials: J
authors.lastname: Lippey
authors.affiliation: Division of Cancer Surgery, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
authors.forename: Rhiannon
authors.initials: R
authors.lastname: Bousounis
authors.affiliation: Division of Cancer Surgery, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
authors.forename: Cori
authors.initials: C
authors.lastname: Behrenbruch
authors.affiliation: Division of Cancer Surgery, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
authors.forename: Bartholomew
authors.initials: B
authors.lastname: McKay
authors.affiliation: Division of Cancer Surgery, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
authors.forename: John
authors.initials: J
authors.lastname: Spillane
authors.affiliation: Division of Cancer Surgery, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.|Department of Surgery, University of Melbourne, Victoria, Australia.
authors.forename: Michael A
authors.initials: MA
authors.lastname: Henderson
authors.affiliation: Division of Cancer Surgery, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
authors.forename: David
authors.initials: D
authors.lastname: Speakman
authors.affiliation: Division of Cancer Surgery, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.|Department of Surgery, University of Melbourne, Victoria, Australia.
authors.forename: David E
authors.initials: DE
authors.lastname: Gyorki
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005456:Fluorescent Dyes / Q000627:therapeutic use*; D006801:Humans; D015552:Injections, Intralesional; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary*; D008875:Middle Aged; D012189:Retrospective Studies; D012395:Rose Bengal / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D016896:Treatment Outcome
chemical_list: D005456:Fluorescent Dyes; D012395:Rose Bengal
keywords: PV-10; Rose Bengal; loco-regional; melanoma; metastasis